We are live on ! Find out more
ITOS

iTeos Therapeutics
ITOS

Delisted

ITOS was delisted on the 28th of August, 2025.

Back to rankings

137 hedge funds and large institutions have $396M invested in iTeos Therapeutics in 2023 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 48 increasing their positions, 39 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 39

1.81% more ownership

Funds ownership: 99.18% → 100.99% (+1.8%)

2% more capital invested

Capital invested by funds: $389M → $396M (+$7.2M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5% less funds holding

Funds holding: 144 → 137 (-7)

14% less first-time investments, than exits

New positions opened: 31 | Existing positions closed: 36

86% less call options, than puts

Call options by funds: $2.04M | Put options by funds: $14.1M

Holders
137
Holders Change
-7
Holders Change %
-4.86%
% of All Funds
2%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
31
Increased
48
Reduced
39
Closed
36
Calls
$2.04M
Puts
$14.1M
Net Calls
-$12M
Net Calls Change
-$16.3M

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$19.8M
2
EC
EcoR1 Capital
California
+$11.1M
3
Renaissance Technologies
Renaissance Technologies
New York
+$3.02M
4
Citigroup
Citigroup
New York
+$2.56M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.91M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$10.2M
2
BlackRock
BlackRock
New York
-$7.82M
3
CS
Candriam SCA
Luxembourg
-$5.6M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$5.48M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$3.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$48.4M – – –
BlackRock
2
BlackRock
New York
$46.7M -$7.82M -789,223 -16%
MAM
3
MPM Asset Management
Massachusetts
$30M – – –
Morgan Stanley
4
Morgan Stanley
New York
$24.8M +$19.8M +2,001,233 +765%
BC
5
Boxer Capital
California
$19.8M – – –
MB
6
MPM BioImpact
Massachusetts
$19.1M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$16.3M -$3.2M -322,817 -18%
BI
8
BVF Inc
California
$13.8M – – –
Citadel Advisors
9
Citadel Advisors
Florida
$12.4M +$1.21M +122,216 +12%
EC
10
EcoR1 Capital
California
$12.2M +$11.1M +1,115,022 New
Millennium Management
11
Millennium Management
New York
$10.6M -$649K -65,444 -6%
SVCM
12
Saturn V Capital Management
Texas
$9.07M -$1.65M -166,524 -17%
Dimensional Fund Advisors
13
Dimensional Fund Advisors
Texas
$8.47M +$716K +72,190 +10%
Goldman Sachs
14
Goldman Sachs
New York
$8.13M +$1.32M +132,856 +22%
DM
15
Deerfield Management
New York
$7.92M – – –
6CM
16
683 Capital Management
New York
$7.83M -$942K -95,000 -12%
Renaissance Technologies
17
Renaissance Technologies
New York
$7.65M +$3.02M +304,900 +77%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$6.23M +$365K +36,773 +7%
State Street
19
State Street
Massachusetts
$6.04M -$10.2M -1,029,938 -65%
Jacobs Levy Equity Management
20
Jacobs Levy Equity Management
New Jersey
$5.85M +$743K +74,949 +16%
AG
21
Artal Group
Luxembourg
$4.38M – – –
IC
22
Ikarian Capital
Texas
$3.79M – – –
Citigroup
23
Citigroup
New York
$3.78M +$2.56M +258,468 +299%
Prudential Financial
24
Prudential Financial
New Jersey
$3.76M +$905K +91,290 +36%
Barclays
25
Barclays
United Kingdom
$3.42M -$96.6K -9,742 -3%
1
2 3 4 5

ITOS Hedge Fund Activity: Q4 2023 in Review

137 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q4 2023, worth a combined $396M — up 1.9% from $389M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of ITOS and 31 opened new positions — a net loss of 5 holders — while 39 trimmed existing stakes and 48 added.

The largest buyer was Morgan Stanley, adding an estimated $19.8M. The largest seller was State Street, cutting an estimated $10.2M.

  • 137 institutional investors held iTeos Therapeutics (ITOS) as of Q4 2023, down from 144 in Q3 2023.
  • Funds reported $396M of iTeos Therapeutics stock for Q4 2023, up 1.9% quarter-over-quarter.
  • 31 funds opened new iTeos Therapeutics positions in Q4 2023 and 36 closed out, a net change of -5 holders.
  • The largest iTeos Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $19.8M added.
  • The largest iTeos Therapeutics seller in Q4 2023 was State Street, an estimated $10.2M sold.

Based on aggregated 13F filings for Q4 2023.